[go: up one dir, main page]

WO2015116852A8 - Methods for treating rheumatoid arthritis by administering an il-6r antibody - Google Patents

Methods for treating rheumatoid arthritis by administering an il-6r antibody Download PDF

Info

Publication number
WO2015116852A8
WO2015116852A8 PCT/US2015/013588 US2015013588W WO2015116852A8 WO 2015116852 A8 WO2015116852 A8 WO 2015116852A8 US 2015013588 W US2015013588 W US 2015013588W WO 2015116852 A8 WO2015116852 A8 WO 2015116852A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibody
rheumatoid arthritis
administering
treating rheumatoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/013588
Other languages
French (fr)
Other versions
WO2015116852A1 (en
Inventor
Anita BOYAPATI
Jennifer Davidson HAMILTON
Jérôme MSIHID
Emmanuelle Cousin
Ling CAI
Stefano FIORE
Janet VAN ADELSBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of WO2015116852A1 publication Critical patent/WO2015116852A1/en
Publication of WO2015116852A8 publication Critical patent/WO2015116852A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods for treating rheumatoid arthritis (RA). Also provided are methods for improving one or more RA-associated parameter(s), methods for decreasing the level of at least one RA-associated biomarker in a subject in need thereof, and methods for treating RA according to the expression levels of one or more RA-associated biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-6 receptor (IL-6R) antagonist such as an anti-IL-6R antibody.
PCT/US2015/013588 2014-01-29 2015-01-29 Methods for treating rheumatoid arthritis by administering an il-6r antibody Ceased WO2015116852A1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201461933156P 2014-01-29 2014-01-29
US61/933,156 2014-01-29
US201461986933P 2014-05-01 2014-05-01
US61/986,933 2014-05-01
US201462011675P 2014-06-13 2014-06-13
US62/011,675 2014-06-13
US201462073638P 2014-10-31 2014-10-31
US62/073,638 2014-10-31
EP14306771 2014-11-05
EP14306771.8 2014-11-05

Publications (2)

Publication Number Publication Date
WO2015116852A1 WO2015116852A1 (en) 2015-08-06
WO2015116852A8 true WO2015116852A8 (en) 2016-06-16

Family

ID=51945814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/013588 Ceased WO2015116852A1 (en) 2014-01-29 2015-01-29 Methods for treating rheumatoid arthritis by administering an il-6r antibody

Country Status (1)

Country Link
WO (1) WO2015116852A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002422A (en) * 2018-08-29 2021-07-15 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
PT1074268E (en) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies
US6670373B1 (en) 1999-10-07 2003-12-30 Eli Lilly And Company Compounds and method for inhibiting MRP1
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CA2652976C (en) * 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
WO2011163566A2 (en) * 2010-06-25 2011-12-29 Tolerx, Inc. Methods of treating patients with immune-related diseases
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
WO2015116852A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
EP4374919A3 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4331585A3 (en) Inhibitors of ret
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX384192B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EP4299133A3 (en) Compositions and methods for the delivery of therapeutics
MY191581A (en) Anti-pd-1 antibodies
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
MX342810B (en) Anti-il-6 receptor antibodies and methods of use.
NZ737399A (en) Ccr2 modulators
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
PH12016502535B1 (en) Interferon alpha and omega antibody antagonists
MX2020011993A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same.
MX2021006732A (en) Beverage nanoemulstions produced by high shear processing.
MY188405A (en) Anti-cd154 antibodies and methods of using them
EP4238994A3 (en) Compositions and methods of treating lupus nephritis
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
EA201692482A1 (en) METHODS OF TREATMENT OF DISEASES BY ANTIBODIES THAT BIND THE RECEPTOR OF COLONYSTIMULATING FACTOR 1 (CSF1R)
EP3761033A3 (en) Method for improving antibody stability
MX2018004829A (en) Methods of measuring factor d activity and potency of factor d inhibitors.
IN2014CH00304A (en)
WO2015116852A8 (en) Methods for treating rheumatoid arthritis by administering an il-6r antibody
CA3013532A1 (en) Liraglutide in cardiovascular conditions
WO2016100745A3 (en) Methods and compositions related to transplant-associated thrombotic microangiopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15706563

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15706563

Country of ref document: EP

Kind code of ref document: A1